What is Micofenolato De Mofetil Bluelife used for?

Micofenolato De Mofetil Bluelife

Active Ingredient:: Mycophenolate Mofetil
Origin:: EU

Micofenolato De Mofetil Bluelife (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Micofenolato De Mofetil Bluelife, is an immunosuppressant presented as an oral formulation for oral use. It is employed to prevent organ transplant rejection and to treat lupus nephritis in adult patients. It is indicated for use in kidney, heart and liver transplantation protocols as well as for managing renal involvement in systemic lupus erythematosus.

GNH India supplies Micofenolato De Mofetil Bluelife as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide, with a focus on quality assurance, regulatory compliance and reliable logistics.

Manufacturer / TM Owner

Axone, Lda.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Mycophenolate Mofetil is used to modulate immune activity in transplant and autoimmune disease settings.
Kidney transplant rejection: helps prevent graft loss by suppressing the recipient's immune response.
Heart transplant rejection: reduces the risk of acute rejection episodes after cardiac transplantation.
Liver transplant rejection: supports long‑term graft survival by inhibiting lymphocyte proliferation.
Lupus nephritis: improves renal outcomes by decreasing immune‑mediated inflammation in systemic lupus erythematosus.

How It Works

Mycophenolate mofetil is a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH). By blocking IMPDH, it reduces synthesis of guanosine nucleotides, which are essential for DNA replication in activated T and B lymphocytes. This selective suppression limits lymphocyte proliferation while sparing most other cell types, providing immunosuppressive activity. The effect is reversible upon drug discontinuation and contributes to reduced immune‑mediated injury in transplanted organs and autoimmune kidneys.

Side Effects

Mycophenolate mofetil may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

Nausea: mild to moderate upset stomach.
Diarrhea: loose stools that may affect hydration.
Headache: transient cranial discomfort.
Increased susceptibility to infections: especially upper respiratory tract infections.

Serious or Rare Side Effects

Leukopenia: significant reduction in white blood cells.
Severe infections: opportunistic or life‑threatening bacterial, viral or fungal infections.
Hepatic toxicity: elevated liver enzymes or hepatitis.
Increased risk of malignancy: such as post‑transplant lymphoproliferative disorder or lymphoma.

Precautions & Warnings

When using Mycophenolate Mofetil, clinicians should observe several precautionary measures to minimize risks.
Blood count monitoring: Perform regular complete blood counts to detect leukopenia or anemia.
Liver function monitoring: Assess hepatic enzymes periodically for signs of toxicity.
Pregnancy avoidance: The drug is contraindicated in pregnancy (Category X); ensure effective contraception.
Renal dose adjustment: Reduce dose in patients with significant renal impairment.
Store at room temperature: Keep in the original packaging, protect from moisture and light.

Avoid Interactions

Mycophenolate Mofetil interacts with several agents that may alter its efficacy or safety.

Major Interactions (Avoid)

Live vaccines: Avoid concurrent use due to risk of infection.
Strong CYP3A4 inducers (e.g., rifampin): May markedly reduce drug exposure.
Concurrent bone‑marrow suppressants (e.g., azathioprine): Increase risk of severe cytopenias.

Moderate Interactions (Monitor Closely)

ACE inhibitors: May increase risk of hyperkalemia and renal dysfunction.
NSAIDs: May exacerbate renal toxicity, especially in patients with compromised kidney function.

Frequently Asked Questions

Micofenolato De Mofetil Bluelife contains mycophenolate mofetil, an immunosuppressant indicated for prevention of organ transplant rejection—including kidney, heart and liver transplants—and for treatment of lupus nephritis in adult

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 09 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.